Company registration number 06579409 (England and Wales)
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
CONTENTS
Page
Statement of financial position
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 9
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
-
0
8,309
Tangible assets
4
545,470
177,737
545,470
186,046
Current assets
Stocks
853,188
531,065
Debtors
5
807,092
321,999
Cash at bank and in hand
429,956
15,985
2,090,236
869,049
Creditors: amounts falling due within one year
6
(3,285,586)
(1,593,885)
Net current liabilities
(1,195,350)
(724,836)
Total assets less current liabilities
(649,880)
(538,790)
Provisions for liabilities
(102,626)
(26,612)
Net liabilities
(752,506)
(565,402)
Capital and reserves
Called up share capital
125
125
Profit and loss reserves
(752,631)
(565,527)
Total equity
(752,506)
(565,402)
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
30 SEPTEMBER 2025
30 September 2025
- 2 -

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 24 July 2026
W M Van Raalte
Director
Company registration number 06579409 (England and Wales)
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 April 2023
125
(11,850)
(11,725)
Period ended 30 September 2024:
Loss and total comprehensive income
-
(553,677)
(553,677)
Balance at 30 September 2024
125
(565,527)
(565,402)
Year ended 30 September 2025:
Loss and total comprehensive income
-
(187,104)
(187,104)
Balance at 30 September 2025
125
(752,631)
(752,506)
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 4 -
1
Accounting policies
Company information

Da Vinci Laboratory Solutions UK & Ireland Limited is a private company limited by shares incorporated in England and Wales. The registered office is Wellbrook Court, Girton, Cambridge, CB3 0NA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The company is dependent on the continued support of the parent company. The parent company does not have any intention to remove its support for a period of at least 12 months from the date on which the balance sheet was signed. Atruet the time of approving the financial statements, and taking into consideration the continued parent company support, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, contract value, costs incurred and costs to complete can be estimated reliably. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets other than goodwill

Development expenditure is the cost of research and development of the identifiable asset.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
5 years
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Demo equipment
20% straight line
Fixtures and fittings
20% straight line
Computers
20% straight line
Motor vehicles
20% straight line
Service equipment
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 7 -
1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.14

Related party exemption

The company has taken advantage of exemption, under the provisions of section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with other 100% group companies.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
13
6
3
Intangible fixed assets
Development costs
£
Cost
At 1 October 2024 and 30 September 2025
316,008
Amortisation and impairment
At 1 October 2024
307,699
Amortisation charged for the year
8,309
At 30 September 2025
316,008
Carrying amount
At 30 September 2025
-
0
At 30 September 2024
8,309
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 8 -
4
Tangible fixed assets
Demo equipment
Fixtures and fittings
Computers
Motor vehicles
Service equipment
Total
£
£
£
£
£
£
Cost
At 1 October 2024
204,862
21,243
14,538
58,660
66,430
365,733
Additions
462,969
-
0
-
0
-
0
-
0
462,969
At 30 September 2025
667,831
21,243
14,538
58,660
66,430
828,702
Depreciation and impairment
At 1 October 2024
64,958
17,568
10,908
29,527
65,035
187,996
Depreciation charged in the year
80,518
1,101
1,338
11,732
547
95,236
At 30 September 2025
145,476
18,669
12,246
41,259
65,582
283,232
Carrying amount
At 30 September 2025
522,355
2,574
2,292
17,401
848
545,470
At 30 September 2024
139,904
3,675
3,630
29,133
1,395
177,737
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
398,806
255,858
Other debtors
3,117
6,924
Prepayments and accrued income
405,169
59,217
807,092
321,999
6
Creditors: amounts falling due within one year
2025
2024
£
£
Amounts owed to group undertakings
1,354,846
1,462,168
Trade creditors
500,093
70,672
Taxation and social security
125,444
6,752
Deferred income
1,048,484
-
0
Other creditors
179,961
10,001
Accruals and deferred income
76,758
44,292
3,285,586
1,593,885
DA VINCI LABORATORY SOLUTIONS UK & IRELAND LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 9 -
7
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
53,878
9,455

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

8
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
21,978
5,987

 

 

9
Related party transactions

Included in other creditors is a loan balance of £1,354,847 (2024: £1,462,168) due to the parent company Labbizz Management BV. The loan is interest fee and repayable on demand.

10
Parent company

The company considers that Labizz Management BV, a company registered at Tramstaat 15, 5611 CM Eindhoven, Netherlands, to be the ultimate parent company by virtue of its 100% shareholding.

 

2025-09-302024-10-01falsefalsefalse24 July 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityW M Van Raalte065794092024-10-012025-09-30065794092025-09-30065794092024-09-3006579409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-09-3006579409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-09-3006579409core:PlantMachinery2025-09-3006579409core:FurnitureFittings2025-09-3006579409core:ComputerEquipment2025-09-3006579409core:MotorVehicles2025-09-3006579409core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-09-3006579409core:PlantMachinery2024-09-3006579409core:FurnitureFittings2024-09-3006579409core:ComputerEquipment2024-09-3006579409core:MotorVehicles2024-09-3006579409core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-09-3006579409core:WithinOneYear2025-09-3006579409core:WithinOneYear2024-09-3006579409core:CurrentFinancialInstrumentscore:WithinOneYear2025-09-3006579409core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3006579409core:ShareCapital2025-09-3006579409core:ShareCapital2024-09-3006579409core:RetainedEarningsAccumulatedLosses2025-09-3006579409core:RetainedEarningsAccumulatedLosses2024-09-3006579409core:ShareCapital2023-03-3106579409core:RetainedEarningsAccumulatedLosses2023-03-3106579409bus:Director12024-10-012025-09-3006579409core:RetainedEarningsAccumulatedLosses2023-04-012024-09-30065794092023-04-012024-09-3006579409core:RetainedEarningsAccumulatedLosses2024-10-012025-09-3006579409core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3006579409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-10-012025-09-3006579409core:PlantMachinery2024-10-012025-09-3006579409core:FurnitureFittings2024-10-012025-09-3006579409core:ComputerEquipment2024-10-012025-09-3006579409core:MotorVehicles2024-10-012025-09-3006579409core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-10-012025-09-3006579409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-09-3006579409core:PlantMachinery2024-09-3006579409core:FurnitureFittings2024-09-3006579409core:ComputerEquipment2024-09-3006579409core:MotorVehicles2024-09-3006579409core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-09-30065794092024-09-3006579409core:CurrentFinancialInstruments2025-09-3006579409core:CurrentFinancialInstruments2024-09-3006579409bus:PrivateLimitedCompanyLtd2024-10-012025-09-3006579409bus:SmallCompaniesRegimeForAccounts2024-10-012025-09-3006579409bus:FRS1022024-10-012025-09-3006579409bus:AuditExemptWithAccountantsReport2024-10-012025-09-3006579409bus:FullAccounts2024-10-012025-09-30xbrli:purexbrli:sharesiso4217:GBP